Zymeworks Common Valuation
| ZYME Stock | USD 22.72 0.70 3.18% |
At this time, the company appears to be undervalued. Zymeworks Common Stock maintains a prevalent Real Value of $27.29 per share. The last-minute price of the company is $22.72. Our model calculates the value of Zymeworks Common Stock from examining the company fundamentals such as Profit Margin of (0.47) %, current valuation of 1.51 B, and Return On Asset of -0.0998 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Zymeworks Common's valuation include:
Price Book 5.52 | Enterprise Value | Enterprise Value Ebitda 0.3383 | Price Sales 13.0861 | Enterprise Value Revenue 11.4048 |
Undervalued
Today
Please note that Zymeworks Common's price fluctuation is not too volatile at this time. Calculation of the real value of Zymeworks Common Stock is based on 3 months time horizon. Increasing Zymeworks Common's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Zymeworks stock is determined by what a typical buyer is willing to pay for full or partial control of Zymeworks Common Stock. Since Zymeworks Common is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Zymeworks Stock. However, Zymeworks Common's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 22.72 | Real 27.29 | Target 35.62 | Hype 22.09 | Naive 23.07 |
The real value of Zymeworks Stock, also known as its intrinsic value, is the underlying worth of Zymeworks Common Stock Company, which is reflected in its stock price. It is based on Zymeworks Common's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Zymeworks Common's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Zymeworks Common Stock helps investors to forecast how Zymeworks stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Zymeworks Common more accurately as focusing exclusively on Zymeworks Common's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Zymeworks Common's intrinsic value based on its ongoing forecasts of Zymeworks Common's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Zymeworks Common's closest peers. If more than one evaluation category is relevant for Zymeworks Common we suggest using both methods to arrive at a better estimate.
Zymeworks Common Cash |
|
Zymeworks Revenue by Product
Zymeworks Common Total Value Analysis
Zymeworks Common Stock is at this time expected to have valuation of 1.51 B with market capitalization of 1.76 B, debt of 18.51 M, and cash on hands of 241.83 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Zymeworks Common fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.51 B | 1.76 B | 18.51 M | 241.83 M |
Zymeworks Common Investor Information
About 99.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 0.84. Zymeworks Common Stock had not issued any dividends in recent years. Based on the analysis of Zymeworks Common's profitability, liquidity, and operating efficiency, Zymeworks Common Stock is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Zymeworks Common Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Zymeworks Common has an asset utilization ratio of 16.48 percent. This indicates that the Company is making $0.16 for each dollar of assets. An increasing asset utilization means that Zymeworks Common Stock is more efficient with each dollar of assets it utilizes for everyday operations.Zymeworks Common Profitability Analysis
Considering Zymeworks Common's profitability and operating efficiency indicators, Zymeworks Common Stock may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Zymeworks Common's ability to earn profits and add value for shareholders.Net Loss | First Reported 2015-03-31 | Previous Quarter 2.3 M | Current Value -19.6 M | Quarterly Volatility 56.4 M |
For Zymeworks Common profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Zymeworks Common Stock to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Zymeworks Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Zymeworks Common's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Zymeworks Common over time as well as its relative position and ranking within its peers.
Zymeworks Common Earnings per Share Projection vs Actual
The next projected EPS of Zymeworks Common is estimated to be -0.21825 with future projections ranging from a low of -0.3125 to a high of -0.0325. Zymeworks Common's most recent 12-month trailing earnings per share (EPS TTM) is at -0.84. Please be aware that the consensus of earnings estimates for Zymeworks Common Stock is based on EPS before non-recurring items and includes expenses related to employee stock options.Zymeworks Common Earnings Estimation Breakdown
The calculation of Zymeworks Common's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Zymeworks Common is estimated to be -0.21825 with the future projection ranging from a low of -0.3125 to a high of -0.0325. Please be aware that this consensus of annual earnings estimates for Zymeworks Common Stock is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.31 Lowest | Expected EPS | -0.03 Highest |
Zymeworks Common Earnings Projection Consensus
Suppose the current estimates of Zymeworks Common's value are higher than the current market price of the Zymeworks Common stock. In this case, investors may conclude that Zymeworks Common is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Zymeworks Common's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 14 | 40.95% | -0.26 | -0.21825 | -0.84 |
Zymeworks Common Ownership Allocation
The majority of Zymeworks Common outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Zymeworks Common Stock to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Zymeworks Common Stock. Please pay attention to any change in the institutional holdings of Zymeworks Common Stock as this could imply that something significant has changed or is about to change at the company.Zymeworks Common Profitability Analysis
The company reported the previous year's revenue of 76.3 M. Net Loss for the year was (122.69 M) with loss before overhead, payroll, taxes, and interest of (8.35 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Zymeworks Common's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Zymeworks Common and how it compares across the competition.
About Zymeworks Common Valuation
The stock valuation mechanism determines Zymeworks Common's current worth on a weekly basis. Our valuation model uses a comparative analysis of Zymeworks Common. We calculate exposure to Zymeworks Common's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Zymeworks Common's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 87.7 M | 92.1 M | |
| Pretax Profit Margin | (1.38) | (1.44) | |
| Operating Profit Margin | (1.62) | (1.70) | |
| Net Loss | (1.45) | (1.52) | |
| Gross Profit Margin | (0.79) | (0.83) |
Zymeworks Common Current Valuation Indicators
Valuation refers to the process of determining the present value of Zymeworks Common Stock and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Zymeworks we look at many different elements of the entity such as Zymeworks's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Zymeworks Common, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Zymeworks Common's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Zymeworks Common's worth.Complementary Tools for Zymeworks Stock analysis
When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |